Markets:

Overview

News

Currencies

International

Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.620 -0.030 (-1.82%)

Streaming Delayed Price Updated: 3:32 PM EST, Jan 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting

October 24, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks ↗

October 17, 2023

Here are the best longevity stocks to consider. Each stock listed comes with their unique reasons to buy them.

Via InvestorPlace

Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023

September 19, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Earnings Preview ↗

August 09, 2023

Via Benzinga

Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells

October 11, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics ↗

September 06, 2023

Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and...

Via Benzinga

Lineage Cell Therapeutics: Q1 Earnings Insights ↗

May 11, 2023

Via Benzinga

Lineage Cell Therapeutics's Return On Capital Employed Overview ↗

March 14, 2023

Via Benzinga

RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

October 05, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference

August 29, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress

September 13, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Why DLocal Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket ↗

August 16, 2023

Gainers

Via Benzinga

Lineage to Present at 2023 International Spinal Research Trust Network Meeting

September 11, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 10, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics

September 06, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023

August 03, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For August 10, 2023 ↗

August 10, 2023

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.

Via Benzinga

Lineage Cell Therapeutics' Lung Cancer Vaccine: Initial Data Reveals Modest, Durable Immune Response ↗

July 24, 2023

Lineage Cell Therapeutics Inc (NYSE: LCTX) and Cancer Research UK revealed primary and secondary endpoint results from the recently completed clinical study of VAC2 in advanced non-small

Via Benzinga

Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer

July 24, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index

May 22, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)

May 09, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023

May 04, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

April 26, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Harley-Davidson, Sportsman's Warehouse And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

April 13, 2023

U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Lineage to Present at 2023 AAPS National Biotechnology Conference

April 18, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

3 Penny Stocks to Buy During Market Downturns ↗

April 10, 2023

If you're looking for penny stocks to buy that can weather economic turmoil, these should make the cut due to their strong fundamentals.

Via InvestorPlace

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 09, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium

March 30, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit

March 20, 2023

From Lineage Cell Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.